Skip to content
Sign In Subscribe
Supplier News

Qualitest cleared to market oral contraceptive

Qualitest Pharmaceuticals has received approval from the Food and Drug Administration for its Emoquette oral contraceptive. The company, acquired late last year by Endo Pharmaceuticals, said Friday that it was cleared by the FDA to market Emoquette (desogestrel and ethinyl estradiol) in 0.15 mg/0.

,   and  Chain Drug Review
1 min read

Table of Contents

HUNTSVILLE, Ala. — Qualitest Pharmaceuticals has received approval from the Food and Drug Administration for its Emoquette oral contraceptive.

The company, acquired late last year by Endo Pharmaceuticals, said Friday that it was cleared by the FDA to market Emoquette (desogestrel and ethinyl estradiol) in 0.15 mg/0.03 mg tablets.

The product is a generic version of Ortho-McNeil Pharmaceuticals’ Ortho-Cept contraceptive.

A combination hormone medication, ethinyl estradiol and desogestrel are designed prevent ovulation. The birth control therapy also causes changes in the cervical mucus and uterine lining, making it more difficult for sperm to reach the uterus and for a fertilized egg to attach to the uterus.

Comments

Related

Latest

FMI: Private brands take hold
Retail News

FMI: Private brands take hold

Perceptions around private brands have changed; they are no longer seen merely as generics or national brand equivalents, Doug Baker, vice president, industry relations at FMI, said in releasing the report, titled “The Power of Private Brands 2024.”

,   and  Chain Drug Review